Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637668 | 1.00 | CALML3 (0.48) | CALML3MAOACYP3A4CYP2D6F10 | |
| Trifluoroacetic Acid SCHEMBL6707503 | 0.93 | CALML3 (0.44) | CALML3MAOACYP3A4CYP2D6F10 | |
| Trifluoroacetic Acid SCHEMBL6707502 | 0.93 | CALML3 (0.44) | CALML3MAOACYP3A4CYP2D6F10 | |
| SCHEMBL6040261 | 0.91 | CALML3 (0.50) | CALML3MAOACYP3A4CYP2D6F10 | |
| SCHEMBL6624270 | 0.91 | CALML3 (0.50) | CALML3MAOACYP3A4CYP2D6F10 | |
| SCHEMBL6634621 | 0.85 | MAOA (0.63) | CALML3MAOAF10MAOB | |
| SCHEMBL6634364 | 0.85 | MAOA (0.54) | CALML3MAOAF10MAOB | |
| SCHEMBL6638909 | 0.82 | CALML3 (0.48) | CALML3MAOACYP3A4CYP2D6F10 | |
| SCHEMBL6638913 | 0.82 | CALML3 (0.48) | CALML3MAOACYP3A4CYP2D6F10 | |
| SCHEMBL6636588 | 0.81 | MAOA (0.50) | CALML3MAOAF10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828317-B2 | Bactericides; gramnegative, grampositive bacteria | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | disclosed |
| EP-1472247-A1 | ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040014746-A1 | Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections | LEUHR GARY W (US) | 2004-01-22 | — | — | US | disclosed |
| WO-2003066631-A1 | ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014746-A1 | Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections | TBCD, THPO, NISCH | CALML3 4231/4885MAOA 2120/4885CYP3A4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.